The companies did not provide detailed data for Tezspire, however, and William Blair’s Matt Phipps said in a note he does not ...

Fiera Capital Corp trimmed its holdings in AstraZeneca PLC (NASDAQ:AZN – Free Report) by 5.9% during the third quarter, according to the company in its most recent filing with the Securities and ...

0.04% of the stock is currently owned by insiders. AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, ...

In good news for those averse to injections, GLP-1 agonist medication is a step closer to being offered in oral pill form, ...

The OBR (Office for Budget Responsibility) anticipates economic output in Britain to expand by 1.8% in 2026 and by 1.5% in ...

AstraZeneca and Amgen's drug could have a new use after positive Phase 3 study results. Elsewhere, Jazz set new plans for a ...

To achieve its revenue target, AstraZeneca plans to launch 20 new medicines by 2030, many of which have the potential to generate over $5bn in peak-year revenue. The company’s strategy involves ...

While it remains unclear why AstraZeneca China President Leon Wang has been detained, news of his arrest comes just days ...

AstraZeneca and Amgen's Phase 3 trial data shows Tezspire significantly reduces nasal polyps and congestion in patients with chronic rhinosinusitis with nasal polyps.

Leerink Partners analyst Andrew Berens has maintained their bullish stance on AZN stock, giving a Buy rating on November 6. Andrew ...